CA2317003A1 - Potentialisateur d'expression genetique - Google Patents

Potentialisateur d'expression genetique Download PDF

Info

Publication number
CA2317003A1
CA2317003A1 CA 2317003 CA2317003A CA2317003A1 CA 2317003 A1 CA2317003 A1 CA 2317003A1 CA 2317003 CA2317003 CA 2317003 CA 2317003 A CA2317003 A CA 2317003A CA 2317003 A1 CA2317003 A1 CA 2317003A1
Authority
CA
Canada
Prior art keywords
expression
gene
transgene
reactivation
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2317003
Other languages
English (en)
Inventor
Hidenori Nakajima
Yasufumi Kaneda
Tomoki Yamano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CA2317003A1 publication Critical patent/CA2317003A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA 2317003 2000-02-28 2000-08-29 Potentialisateur d'expression genetique Abandoned CA2317003A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP052582/2000 2000-02-28
JP2000052582 2000-02-28

Publications (1)

Publication Number Publication Date
CA2317003A1 true CA2317003A1 (fr) 2001-08-28

Family

ID=18574077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2317003 Abandoned CA2317003A1 (fr) 2000-02-28 2000-08-29 Potentialisateur d'expression genetique

Country Status (1)

Country Link
CA (1) CA2317003A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1426054A1 (fr) * 2001-08-21 2004-06-09 Fujisawa Pharmaceutical Co., Ltd. Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale
EP1595952A1 (fr) * 2003-02-19 2005-11-16 Astellas Pharma Inc. Procede d'evaluation de l'effet antitumoral d'un inhibiteur d'histone desacetylase
US7488712B2 (en) 2002-02-20 2009-02-10 Kyushu Institute Of Technology Histone deacetylase inhibitors and methods for producing the same
US7662778B2 (en) 2003-06-20 2010-02-16 Riken Histone deacetylase inhibitor and process for producing the same
WO2012135498A3 (fr) * 2011-03-29 2013-04-04 Dr. Baker Says, Inc. Complément nutritionnel comprenant une composition d'huile de noix et de graine
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1426054A1 (fr) * 2001-08-21 2004-06-09 Fujisawa Pharmaceutical Co., Ltd. Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale
EP1426054A4 (fr) * 2001-08-21 2006-09-13 Astellas Pharma Inc Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale
US8470783B2 (en) 2001-08-21 2013-06-25 Astellas Pharma Inc. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
US7488712B2 (en) 2002-02-20 2009-02-10 Kyushu Institute Of Technology Histone deacetylase inhibitors and methods for producing the same
EP1595952A1 (fr) * 2003-02-19 2005-11-16 Astellas Pharma Inc. Procede d'evaluation de l'effet antitumoral d'un inhibiteur d'histone desacetylase
EP1595952A4 (fr) * 2003-02-19 2008-05-21 Astellas Pharma Inc Procede d'evaluation de l'effet antitumoral d'un inhibiteur d'histone desacetylase
US7662778B2 (en) 2003-06-20 2010-02-16 Riken Histone deacetylase inhibitor and process for producing the same
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US9259452B2 (en) 2006-06-08 2016-02-16 Gelgene Corporation Deacetylase inhibitor therapy
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US9518094B2 (en) 2010-07-12 2016-12-13 Celgene Corporation Romidepsin solid forms and uses thereof
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9624271B2 (en) 2010-07-12 2017-04-18 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
WO2012135498A3 (fr) * 2011-03-29 2013-04-04 Dr. Baker Says, Inc. Complément nutritionnel comprenant une composition d'huile de noix et de graine
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9468664B2 (en) 2013-12-27 2016-10-18 Celgene Corporation Romidepsin formulations and uses thereof
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9782451B2 (en) 2013-12-27 2017-10-10 Celgene Corporation Romidepsin formulations and uses thereof
US9795650B2 (en) 2013-12-27 2017-10-24 Celgene Corporation Romidepsin formulations and uses thereof

Similar Documents

Publication Publication Date Title
CN103987847B (zh) 胺阳离子脂质及其用途
JPH07503372A (ja) 生体外遺伝子導入
CA2317003A1 (fr) Potentialisateur d'expression genetique
US20230220422A1 (en) Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
CA2134773A1 (fr) Methodes et compositions pour genotherapie in vivo
JP2003277272A (ja) ＤＮＡ損傷剤およびр５３を含有する組成物
EP1471944A2 (fr) Composition pharmaceutique ameliorant le transfert de gene in vivo
US20230348937A1 (en) Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein fusogenic lipid nanoparticles and methods of manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease
EP0702518B1 (fr) Traitement des maladies vasculaires degeneratives par modulation de l'activite ou de la production d'oxyde nitrique endogene
JPH08506722A (ja) 腫瘍を治療するためのレトロウイルスベクターおよびそれらを含む細胞系統
JP2001521740A (ja) 遺伝子治療用の高温誘導性発現ベクター及びその使用方法
WO1997039135A1 (fr) Expression renforcee de transgenes
Daftary et al. Reproductive tract gene transfer
US6524571B1 (en) Methioninase gene therapy for tumor treatment
JP2001316283A (ja) 遺伝子発現増強剤
CA2557326A1 (fr) Traitement contre la reapparition de cancers au moyen de p53 et de radiotherapies et chimiotherapies
ES2367802T3 (es) Medicamento capaz de inhibir la activación del factor de transcripción klf5.
JP2022552378A (ja) パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ
JP3713290B2 (ja) 抗癌剤
JP2022513159A (ja) Ｒｎａを調節する方法
JPWO2005074988A1 (ja) 神経細胞分化誘導剤
Smolarczyk et al. Negligible induction of IFN-γ, IL-12 and TNF-α by DNA-PEI 750 kDa/albumin complexes
WO2023054242A1 (fr) Nanoparticules lipidiques utilisées pour le transport d'acides nucléiques dans des cellules endothéliales lymphatiques
CZ188299A3 (cs) Transfekční přípravek vhodný pro genovou terapii, který obsahuje rekombinantní virus a transfekční činidlo
US20240002818A1 (en) Mammalian mobile element compositions, systems and therapeutic applications

Legal Events

Date Code Title Description
FZDE Dead